Respiratory syncytial virus (RSV) - Pipeline Insight, 2024

This “Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Respiratory Syncytial Virus (RSV) Understanding

Respiratory Syncytial Virus (RSV): Overview

Respiratory syncytial virus (RSV) is a very common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age 4 years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. Outbreaks typically occur in winter and early spring. RSV is the most common cause of lower respiratory tract illness in young infants and is responsible for more than 50,000 hospitalizations every year in the United States in children under the age of 5 years. The first infection often progresses from an upper respiratory tract illness with congestion and fever to involve the lower respiratory tract, most commonly causing bronchiolitis and sometimes pneumonia with cough and difficulty breathing. Later infections usually involve only the upper respiratory tract. Children who have had bronchiolitis are more likely to be diagnosed with asthma when they are older.

Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Respiratory Syncytial Virus (RSV) pipeline landscape is provided which includes the disease overview and Respiratory Syncytial Virus (RSV) treatment guidelines. The assessment part of the report embraces, in depth Respiratory Syncytial Virus (RSV) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Respiratory Syncytial Virus (RSV) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Respiratory Syncytial Virus (RSV) R&D. The therapies under development are focused on novel approaches to treat/improve Respiratory Syncytial Virus (RSV).

Respiratory Syncytial Virus (RSV) Emerging Drugs Chapters

This segment of the Respiratory Syncytial Virus (RSV) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Respiratory Syncytial Virus (RSV) Emerging Drugs

GSK3844766A: GlaxoSmithKlineThis candidate vaccine contains a recombinant subunit pre-fusion RSV antigen (RSVPreF3) combined with GSK’s proprietary AS01 adjuvant, which is also used in GSK’s shingles vaccine. Currently, it is in phase III of development stage for the treatment of Respiratory Syncytial Virus (RSV).

Nirsevimab (MEDI-8897): MedImmuneMEDI8897 is a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV), the most prevalent cause of LRTI among infants and young children. Currently, it is in phase III of development stage.

Sisunatovir: ReViralSisunatovir is an orally administered fusion inhibitor designed to block RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Preclinical tests showed sisunatovir to have an excellent toxicity profile with an attractive therapeutic index. In Phase 1 clinical studies, sisunatovir showed excellent exposure with no serious adverse events being reported. In 2018, results from a Phase 2a challenge study in healthy adult volunteers were reported in which sisunatovir produced statistically significant reductions in viral load and clinical symptoms. ReViral has initiated two international multicentre Phase 2 clinical studies of sisunatovir in pediatric and adult high-risk patient populations

Respiratory Syncytial Virus (RSV): Therapeutic Assessment

This segment of the report provides insights about the different Respiratory Syncytial Virus (RSV) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Respiratory Syncytial Virus (RSV)

There are approx. 50+ key companies which are developing the therapies for Respiratory Syncytial Virus (RSV). The companies which have their Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Respiratory Syncytial Virus (RSV) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Respiratory Syncytial Virus (RSV): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Respiratory Syncytial Virus (RSV) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Respiratory Syncytial Virus (RSV) drugs.

Respiratory Syncytial Virus (RSV) Report Insights

• Respiratory Syncytial Virus (RSV) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Respiratory Syncytial Virus (RSV) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Respiratory Syncytial Virus (RSV) drugs?
• How many Respiratory Syncytial Virus (RSV) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Respiratory Syncytial Virus (RSV)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Respiratory Syncytial Virus (RSV) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Respiratory Syncytial Virus (RSV) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GlaxoSmithKline
• MedImmune
• ReViral
• Pfizer
• Sanofi
• BioComo
• IMV
• Shionogi
• Aridis Pharmaceuticals
• ADMA Biologics
• Enanta Pharmaceuticals
• Merck Sharp & Dohme
• Janssen Research & Development
• Ark Biosciences
• BlueWillow Biologics
• Meissa Vaccines
• Alios BioPharma
• Codagenix
• Advance Vaccine Laboratories
• Bavarian Nordic
• ModernaTX, Inc.
• Virometix
• Airway Therapeutics LLC
• AlloVir Inc
• Anima Biotech Inc
• Aridis Pharmaceuticals Inc
• Atea Pharmaceuticals Inc
• Atriva Therapeutics
• Calder Biosciences Inc
• Cidara Therapeutics Inc
• Clover Biopharmaceuticals
• Curevac AG
• Enyo Pharma SA
• HanaVax Inc.
• Icosavax Inc
• IDBiologics Inc
• Pneumagen Ltd
• Riboscience LLC
• Signia Therapeutics

Key Products

• GSK3844766A
• Nirsevimab (MEDI-8897)
• Sisunatovir
• RSV F protein vaccine
• Novavax
• Combination seasonal influenza RSV nanoparticle vaccine
• NanoFlu/NVX CoV 2373/RSV
• RSVpreF
• SP 0125
• BC-0004
• GSK 3888550A
• DPX RSV Vaccine
• AR 201
• ASCENIV
• EDP 938
• MK 1654
• Rilematovir
• GSK 3003891A
• JNJ 64400141
• Ziresovir
• JNJ 64213175
• MV-012-968
• ALS-008176
• CodaVax-RSV
• BARS13
• MVA-BN-RSV
• mRNA-1345
• V-306
• ALVR106
• AR-201
• AT-889
• ATR-002
• IVX-121
• RBS-3149

This product will be delivered within 1-3 business days.